CSF CA 15-3 in breast cancer-related leptomeningeal metastases. 2014

Emilie Le Rhun, and Andrew Kramar, and Sophie Salingue, and Marie Girot, and Isabelle Rodrigues, and Audrey Mailliez, and Fahed Zairi, and Edgar Bakhache, and Yves Marie Robin, and Sophie Taillibert, and François Dubois, and Jacques Bonneterre, and Marc C Chamberlain
Breast Unit, Department of Medical Oncology, Oscar Lambret Center, 59 020, Lille Cedex, France, le_rhun@yahoo.fr.

The sensitivity of CSF cytology, the standard method for diagnosis of leptomeningeal metastases (LM), is low. Serum cancer antigen 15-3 (CA 15-3) is frequently used for the monitoring of patients with breast cancer (BC) and is a laboratory test available in most centers. The aim of the current study was to determine the feasibility of measuring CSF CA 15-3 and CA 15-3 CSF/serum ratio in patients with BC-related LM. Serum and CSF CA 15-3 values were evaluated in 20 BC patients with LM (Group 1), 20 patients with LM from other primary cancers (Group 2), 20 BC patients with parenchymal brain metastases only (Group 3) and 20 controls (Group 4). CSF and serum were collected on the same day. Serum and CSF CA 15-3 were assessed by an automatized immuno-enzymatic technology (TRACE(®) technology, KRYPTOR Automate, Brahms Society, France). In univariate analysis, BC patients with LM (Group 1) compared to other groups, a significantly elevated serum CA 15-3 (median 51 U/ml, range 12-2819) and CSF CA 15-3 (median 8.7 U/ml, range 0.1-251) was observed. Additionally, the CSF/serum ratio of CA 15-3 was significantly higher in this group of patients (median 0.18, range 0.002-4.40). Multivariate analysis identified a cut-off for CSF CA15-3 with 80 % sensitivity and 70 % specificity. CONCLUSIONS The current study confirms the feasibility of determining CSF CA 15-3 using a widely available technology. Evaluation of the CSF CA 15-3 may be useful in the diagnosis and management of BC-related LM but further studies are needed.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D008297 Male Males
D008577 Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord. Intracranial Meningeal Neoplasms,Spinal Meningeal Neoplasms,Benign Meningeal Neoplasms,Leptomeningeal Neoplasms,Malignant Meningeal Neoplasms,Meningeal Cancer,Meningeal Neoplasms, Benign,Meningeal Neoplasms, Intracranial,Meningeal Neoplasms, Malignant,Meningeal Tumors,Neoplasms, Leptomeningeal,Neoplasms, Meningeal,Benign Meningeal Neoplasm,Cancer, Meningeal,Cancers, Meningeal,Intracranial Meningeal Neoplasm,Leptomeningeal Neoplasm,Malignant Meningeal Neoplasm,Meningeal Cancers,Meningeal Neoplasm,Meningeal Neoplasm, Benign,Meningeal Neoplasm, Intracranial,Meningeal Neoplasm, Malignant,Meningeal Neoplasm, Spinal,Meningeal Neoplasms, Spinal,Meningeal Tumor,Neoplasm, Benign Meningeal,Neoplasm, Intracranial Meningeal,Neoplasm, Leptomeningeal,Neoplasm, Malignant Meningeal,Neoplasm, Meningeal,Neoplasm, Spinal Meningeal,Neoplasms, Benign Meningeal,Neoplasms, Intracranial Meningeal,Neoplasms, Malignant Meningeal,Neoplasms, Spinal Meningeal,Spinal Meningeal Neoplasm,Tumor, Meningeal,Tumors, Meningeal
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D005260 Female Females
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon

Related Publications

Emilie Le Rhun, and Andrew Kramar, and Sophie Salingue, and Marie Girot, and Isabelle Rodrigues, and Audrey Mailliez, and Fahed Zairi, and Edgar Bakhache, and Yves Marie Robin, and Sophie Taillibert, and François Dubois, and Jacques Bonneterre, and Marc C Chamberlain
August 2018, Clinical biochemistry,
Emilie Le Rhun, and Andrew Kramar, and Sophie Salingue, and Marie Girot, and Isabelle Rodrigues, and Audrey Mailliez, and Fahed Zairi, and Edgar Bakhache, and Yves Marie Robin, and Sophie Taillibert, and François Dubois, and Jacques Bonneterre, and Marc C Chamberlain
July 1988, Bollettino della Societa italiana di biologia sperimentale,
Emilie Le Rhun, and Andrew Kramar, and Sophie Salingue, and Marie Girot, and Isabelle Rodrigues, and Audrey Mailliez, and Fahed Zairi, and Edgar Bakhache, and Yves Marie Robin, and Sophie Taillibert, and François Dubois, and Jacques Bonneterre, and Marc C Chamberlain
January 1994, La Revue de medecine interne,
Emilie Le Rhun, and Andrew Kramar, and Sophie Salingue, and Marie Girot, and Isabelle Rodrigues, and Audrey Mailliez, and Fahed Zairi, and Edgar Bakhache, and Yves Marie Robin, and Sophie Taillibert, and François Dubois, and Jacques Bonneterre, and Marc C Chamberlain
November 2020, Cancer medicine,
Emilie Le Rhun, and Andrew Kramar, and Sophie Salingue, and Marie Girot, and Isabelle Rodrigues, and Audrey Mailliez, and Fahed Zairi, and Edgar Bakhache, and Yves Marie Robin, and Sophie Taillibert, and François Dubois, and Jacques Bonneterre, and Marc C Chamberlain
January 2013, American journal of cancer research,
Emilie Le Rhun, and Andrew Kramar, and Sophie Salingue, and Marie Girot, and Isabelle Rodrigues, and Audrey Mailliez, and Fahed Zairi, and Edgar Bakhache, and Yves Marie Robin, and Sophie Taillibert, and François Dubois, and Jacques Bonneterre, and Marc C Chamberlain
September 1999, Annals of clinical biochemistry,
Emilie Le Rhun, and Andrew Kramar, and Sophie Salingue, and Marie Girot, and Isabelle Rodrigues, and Audrey Mailliez, and Fahed Zairi, and Edgar Bakhache, and Yves Marie Robin, and Sophie Taillibert, and François Dubois, and Jacques Bonneterre, and Marc C Chamberlain
May 2013, Anticancer research,
Emilie Le Rhun, and Andrew Kramar, and Sophie Salingue, and Marie Girot, and Isabelle Rodrigues, and Audrey Mailliez, and Fahed Zairi, and Edgar Bakhache, and Yves Marie Robin, and Sophie Taillibert, and François Dubois, and Jacques Bonneterre, and Marc C Chamberlain
January 2015, Acta medica academica,
Emilie Le Rhun, and Andrew Kramar, and Sophie Salingue, and Marie Girot, and Isabelle Rodrigues, and Audrey Mailliez, and Fahed Zairi, and Edgar Bakhache, and Yves Marie Robin, and Sophie Taillibert, and François Dubois, and Jacques Bonneterre, and Marc C Chamberlain
December 1993, Harefuah,
Emilie Le Rhun, and Andrew Kramar, and Sophie Salingue, and Marie Girot, and Isabelle Rodrigues, and Audrey Mailliez, and Fahed Zairi, and Edgar Bakhache, and Yves Marie Robin, and Sophie Taillibert, and François Dubois, and Jacques Bonneterre, and Marc C Chamberlain
January 2000, The International journal of biological markers,
Copied contents to your clipboard!